Most Clicked StoriesMore >


Cost to develop new drug is $2.56B, Tufts center reports

BIO SmartBrief | Nov 20, 2014

The cost of bringing a new drug to market is $2.56 billion, according to a report from the Tufts Center for the Study of Drug Development. The figure is more than double the center's last estimate of an inflation-adjusted $1.04 billion in 2003. Bloomberg (11/18) Reuters (11/18) American City Business Journals (11/18)


Actavis agrees to pay $66B to purchase Allergan

BIO SmartBrief | Nov 18, 2014

Change needed for drug pricing that returns investment, CMO says

BIO SmartBrief | Nov 19, 2014

Gilead buys Knight Therapeutics' priority-review voucher for $125M

BIO SmartBrief | Nov 20, 2014

Sanofi drug for multiple sclerosis wins FDA approval

BIO SmartBrief | Nov 17, 2014

Geron licenses myelofibrosis drug to Janssen in potential $935M deal

BIO SmartBrief | Nov 14, 2014

Merck KGaA and Pfizer join forces on cancer immunotherapy

BIO SmartBrief | Nov 18, 2014

BIO chief urges Congress to increase BARDA, biodefense funding

BIO SmartBrief | Nov 17, 2014

Study: Pharma competition rules influence drug prices, development

BIO SmartBrief | Nov 19, 2014

Precision Therapeutics rebrands, appoints new execs

BIO SmartBrief | Nov 14, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the BIO CEO & Investor Conference!

BIO SmartBrief | Nov 21, 2014

Industrial biotechnology with a French twist!

BIO SmartBrief | Nov 20, 2014

Faster & better connections with quality R&D vendors

BIO SmartBrief | Nov 19, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Nov 17, 2014

Summer 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Nov 10, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more